Biogen (NASDAQ:BIIB) Trading Down 7.3% – Here’s What Happened

Shares of Biogen Inc. (NASDAQ:BIIB) dropped 7.3% on Tuesday . The company traded as low as $192.70 and last traded at $193.7590. Approximately 344,619 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 1,268,935 shares. The stock had previously closed at $209.03.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen and Eisai announced FDA approval of LEQEMBI IQLIK, the first at-home initiation dose for early Alzheimer’s disease, which could improve convenience, access, and treatment adoption. Article Title
• Positive Sentiment: New AAIC 2026 data showed Biogen’s tau-targeting drug diranersen reduced cognitive decline and tau biomarkers, supporting advancement into confirmatory Phase 3 development. Article Title
• Neutral Sentiment: Biogen also reported that LEQEMBI subcutaneous data showed comparable efficacy and safety to IV dosing, reinforcing the commercial case for its Alzheimer’s franchise. Article Title
• Neutral Sentiment: Several analyst notes and a Truist upgrade to Buy helped sentiment ahead of the data releases, with price targets generally implying upside. Article Title
• Negative Sentiment: Despite the encouraging readouts, investors are focusing on the fact that diranersen’s Phase 2 CELIA study missed its primary endpoint earlier, and the newer results were described as mixed rather than definitive. Article Title
• Negative Sentiment: Biogen is also facing an earnings overhang from disclosed R&D and milestone expenses, which could weigh on near-term profitability even as pipeline news improves. Article Title

Analyst Ratings Changes

A number of research analysts recently issued reports on BIIB shares. Mizuho dropped their target price on shares of Biogen from $236.00 to $221.00 and set an “outperform” rating on the stock in a research report on Monday, June 15th. UBS Group raised shares of Biogen from a “neutral” rating to a “buy” rating and lifted their price target for the company from $185.00 to $225.00 in a research note on Wednesday, April 22nd. Guggenheim upped their price objective on shares of Biogen from $246.00 to $260.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Wall Street Zen raised shares of Biogen from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Freedom Capital raised Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $220.04.

Biogen Price Performance

The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The business’s fifty day moving average price is $198.64 and its 200-day moving average price is $188.40. The stock has a market capitalization of $28.13 billion, a price-to-earnings ratio of 20.44 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. The business had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, research analysts forecast that Biogen Inc. will post 13.77 EPS for the current year.

Institutional Investors Weigh In On Biogen

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in shares of Biogen by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock worth $3,070,514,000 after acquiring an additional 157,857 shares in the last quarter. Geode Capital Management LLC grew its position in Biogen by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock worth $736,435,000 after purchasing an additional 130,618 shares in the last quarter. Norges Bank purchased a new stake in Biogen in the 4th quarter valued at about $464,408,000. Invesco Ltd. increased its stake in Biogen by 4.2% in the 3rd quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock valued at $338,731,000 after buying an additional 98,001 shares during the last quarter. Finally, Morgan Stanley boosted its stake in shares of Biogen by 3.3% in the 4th quarter. Morgan Stanley now owns 2,325,013 shares of the biotechnology company’s stock worth $409,180,000 after buying an additional 73,478 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.